AQR Capital Management
CRSP icon

AQR Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

AQR Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.56M Buy
28,597
+6,329
+28% +$334K ﹤0.01% 2772
2026
Q1 		$1.06M Buy
22,268
+1,522
+7% +$80.3K ﹤0.01% 2732
2025
Q4 		$1.09M Sell
20,746
-7,626
-27% -$457K ﹤0.01% 2495
2025
Q3 		$1.84M Buy
28,372
+6,758
+31% +$388K ﹤0.01% 2022
2025
Q2 		$1.05M Sell
21,614
-3,692
-15% -$143K ﹤0.01% 2179
2025
Q1 		$861K Buy
+25,306
New +$1.07M ﹤0.01% 2124
2022
Q3 		– Sell
-8,505
Closed -$517K – 2222
2022
Q2 		$517K Sell
8,505
-578
-6% -$34K ﹤0.01% 1672
2022
Q1 		$570K Buy
9,083
+2,310
+34% +$145K ﹤0.01% 1770
2021
Q4 		$513K Buy
6,773
+2,911
+75% +$254K ﹤0.01% 1817
2021
Q3 		$432K Buy
3,862
+1,661
+75% +$209K ﹤0.01% 1917
2021
Q2 		$356K Buy
+2,201
New +$268K ﹤0.01% 1998

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

AQR Capital Management's CRSP Position: Q2 2026 in Review

AQR Capital Management increased its CRISPR Therapeutics (CRSP) stake by 28% in Q2 2026, buying an estimated $334K and bringing the position to 28,597 shares worth $1.56M. The position accounts for ﹤0.01% of the portfolio, ranked #2772.

AQR Capital Management first reported a position in CRSP in Q2 2021 and has held it in 11 quarters since. The position peaked at $1.84M in Q3 2025. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • AQR Capital Management held 28,597 shares of CRISPR Therapeutics worth $1.56M as of Q2 2026.
  • AQR Capital Management bought 6,329 CRISPR Therapeutics shares in Q2 2026, an estimated $334K.
  • CRISPR Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q2 2026, its #2772 holding.
  • AQR Capital Management first reported a position in CRISPR Therapeutics in Q2 2021 and has held it in 11 quarters since.
  • AQR Capital Management's CRISPR Therapeutics position peaked at $1.84M in Q3 2025.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.